Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My apologize, wrong board.
Why would you not want shorted shares? Once this starts to move that will create even more shares that have to be covered, creating any even bigger demand for shares.
The boat has run into a stiff current, might take another 4 months to get here. How long will those pads last before they begin to break down?
Isn't that the answer to the entire universe? LOL
Lakers and Dom, please no smarta** comments about these questions for the green one.
Georgie Green, why are you so adamant about PYCT? Are you hoping / wishing? Do you have access to information that no one else is aware of? Do you have direct contact with the those in Hong Kong? I am curious why you preach from the highest mountain.
Now that's any interesting move up.
Thanks Carnac, it's pleasant to have someone post a conversation with thoughtful insight rather than taking it as an opportunity to be a cheerleader and promote.
Ah, come on, someone has to provide material for comic relief.
Sooner, the hours are ticking by, yet you have not posted the news!
So, it's been over 35 minutes, where's the news?
I think he knows, it's getting others to quit playing politics and aggressively move towards the future.
LII moving up without any volume! Oh Yah!
Would like see it hit the wires, not just from their website.
I'm sure all of the shareholders who either voted for the RS or just didn't vote period, are kicking themselves in the rear this AM. Watch the price fall, How Low Will It Go!
The web presence.
http://www.planetimpactinc.com/
No, it usually takes two or three. LOL
They seem to always need a morning constitution, don't they? LOL
If you were right all of the time I would have already sold my shares for .10! Hey, I have a broken clock that's right twice a day.
That would be my guess, removed from public view until actual PR released to announce the happenings.
Is the website down? That's what appears to me. Also the Pristine Pharma site appears to be down.
Right On Investo! I'm one of those who have been around here for a long time and read what was related to you by Tom. Good riddance to him!
Eating quickly through the .35's
Huge volume of shares being dumped with this news.
Can you supply his email contact info, as the last one I had no longer works? Thanks
One note: The new Michelex website does not reflect the 7/30 news of the Pristine Pharma acquisition like the PPC site does. Why?
"What has" what?
They have officially re-incorporated as a Florida corp., they can now move forward with other projects. This is what has been holding a lot of activity up.
Check this out everyone!
http://michelex.com/html/index.aspx?page=home
Don't think so. Follow the link to the website and select the NEWS tab, the very first item is dated 7/30.
For those interested in the filings:
http://www.sec.gov/Archives/edgar/data/793981/000122752810000121/0001227528-10-000121-index.htm
Loading up??? Heck, what even happened to George! Did he bio-degrade, after all it's been about 70 days!
This has been going on for some time with XOMA and what appears to be happening is that they are attempting to sell a large number of shares to support the business, including rather exorbitant salaries and executive options. To this end they release good news, not fake news, but valid favorable news, but then dump tons of shares into the market in an attempt to garner cash for the business. I recently voted my shares not to allow the reverse split as some new option compensation to those that put us in this position in the first place. The BOD and CEO need to be replaced, NOW!
I posted that news when it came out yesterday morning, and I think you can see how the stock reacted.
Might have been a dump, but never really saw a pump.
It was fun while it lasted. LOL
Holy Cow! This thing is all over the place. Yea!
Are you ready for another day of company dumping of shares - NEWS!
PRESS RELEASE
July 29, 2010, 8:00 a.m. EDT · Recommend · Post:
XOMA 052 Orphan Drug Designation for Behcet's Disease Recommended by European Medicines Agency
BERKELEY, Calif., Jul 29, 2010 (GlobeNewswire via COMTEX) -- XOMA Ltd. (XOMA 0.33, +0.03, +11.45%) , a leader in the discovery and development of therapeutic antibodies, announced that the Committee for Orphan Medical Products of the European Medicines Agency (EMA) has adopted a positive opinion and recommends the granting of orphan medicinal product designation for XOMA 052, an antibody to interleukin-1 beta, for the treatment of Behcet's disease. Positive opinions are submitted to the European Commission for decision and are generally adopted within 30 days of receipt.
The EMA's orphan drug program is designed to promote the development of drugs to treat life-threatening or chronically debilitating conditions with a prevalence of up to five in 10,000 persons in the European Union (EU). The designation provides EU market exclusivity for up to ten years following approval for the given indication. Other potential benefits include protocol assistance, direct access to centralized marketing authorization procedures and financial incentives.
In June 2010, XOMA announced positive results from an open-label pilot study of XOMA 052 in Behcet's disease patients who were suffering from vision-threatening disease exacerbations, known as uveitis, despite maximal doses of immunosuppressive medicines. All seven patients who enrolled in the trial displayed rapid reduction of intraocular inflammation and improvement in visual acuity or other ophthalmic measures following a single treatment with XOMA 052. Five patients received a second infusion to blunt a developing exacerbation, and all responded to the second infusion. The drug appeared to be safe, and no drug-related adverse events were reported. Preliminary results were presented at the Annual Congress of the European League Against Rheumatism (EULAR) in Rome, Italy and at the International Congress on Behcet's Disease in London earlier this month.
About Behcet's Disease
Behcet's (pronounced beh-CHETS) disease is an orphan disease that causes chronic inflammation of the blood vessels, or vasculitis. Major symptoms can affect the neurological, pulmonary, gastrointestinal and cardiovascular systems, and hallmarks of the disease include uveitis, or inflammation of the intraocular tissues of the eye, and painful ulcers in the mouth and on the genitals. Behcet's disease most commonly affects men and women in their twenties, thirties and forties, and it is typically more severe in men. More than 12,000 patients in the EU are estimated to suffer from Behcet's disease.
About XOMA 052
XOMA 052 is a potent monoclonal antibody with the potential to improve the treatment of patients with a wide variety of inflammatory diseases. XOMA 052 binds strongly to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine involved in diseases including Type 2 diabetes, cardiovascular disease, rheumatoid arthritis, gout and auto-inflammatory diseases. IL-1 is a well-validated therapeutic target, with three marketed IL-1 inhibitors that have been used by more than 200,000 patients overall. By binding to IL-1 beta, XOMA 052 inhibits the activation of the IL-1 receptor, thereby preventing the cellular signaling events that produce inflammation.
XOMA is conducting two Phase 2 clinical trials of XOMA 052 in patients with Type 2 diabetes and a Phase 2 trial in Type 1 diabetes and has completed a Phase 2 clinical trial in uveitis of Behcet's disease. The Phase 2 trials follow a successful 98 patient Phase 1 program in Type 2 diabetes patients in which XOMA 052 was shown to be well-tolerated, demonstrated evidence of biological activity in diabetes measures and cardiovascular biomarkers, and had a half-life that may provide convenient dosing of once per month or less frequently. The company has also demonstrated the potential for XOMA 052 in in vivo models of atherosclerosis and cardiac remodeling and in an in vitro model using human myeloma, or plasma cell cancer, cells.
About XOMA
XOMA discovers, develops and manufactures novel antibody therapeutics for its own proprietary pipeline as well as through license and collaborative agreements with pharmaceutical and biotechnology companies, and under its contracts with the U.S. government. The company's proprietary product pipeline includes:
-- XOMA 052, an anti-IL-1 beta antibody in Phase 2 clinical development for
Type 2 diabetes with cardiovascular biomarkers, Type 1 diabetes, and
with potential for the treatment of a wide range of inflammatory
conditions. XOMA 052 also has demonstrated positive clinical benefit in
a proof-of-concept trial for the treatment of vision-threatening uveitis
of Behcet's disease.
-- XOMA 3AB, an antibody candidate in pre-IND studies to neutralize the
botulinum toxin, among the most deadly potential bioterror threats,
under development through funding provided by the National Institute of
Allergy and Infectious Diseases of the National Institutes of Health
(Contract # HHSN266200600008C).
-- A preclinical pipeline with candidates in development for several
diseases.
In addition to its proprietary pipeline, XOMA develops products with premier pharmaceutical companies including Novartis AG, Schering Corporation, a subsidiary of Merck & Co., Inc. and Takeda Pharmaceutical Company Limited.
XOMA's technologies have contributed to the success of marketed antibody products, including LUCENTIS(R) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(R) (certolizumab pegol) for rheumatoid arthritis and Crohn's disease.
The company has a premier antibody discovery and development platform that incorporates an unmatched collection of antibody phage display libraries and proprietary Human Engineering(TM), affinity maturation, Bacterial Cell Expression (BCE) and manufacturing technologies. BCE is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. As a result, 60 pharmaceutical and biotechnology companies have signed BCE licenses, and several licensed product candidates are in clinical development.
XOMA has a fully integrated product development infrastructure, extending from pre-clinical science to approval, and a team of about 215 employees at its Berkeley, California location. For more information, please visit http://www.xoma.com.
Forward-Looking Statements
Certain statements contained herein concerning product development and capabilities of XOMA's technologies or that otherwise relate to future periods are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market.
These risks, including those related to inability to comply with NASDAQ's continued listing requirements; the generally unstable nature of current economic conditions; the results of discovery research and pre-clinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); changes in the status of existing collaborative and licensing relationships; the ability of collaborators, licensees and other third parties to meet their obligations; XOMA's ability to meet the demands of the United States government agency with which it has entered into its government contracts; competition; market demands for products; scale-up and marketing capabilities; availability of additional licensing or collaboration opportunities; international operations; share price volatility; XOMA's financing needs and opportunities; uncertainties regarding the status of biotechnology patents; uncertainties as to the costs of protecting intellectual property; and risks associated with XOMA's status as a Bermuda company, are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings. Consider such risks carefully when considering XOMA's prospects.
The XOMA Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5960
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: XOMA Ltd.
Somebody trying to get this thing moving. Keep dropping the bid X ask without any sells or buys.